GHENT, Belgium & MARCHE-EN-FAMENNE, Belgium--(BUSINESS WIRE)--May 19, 2026--
ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513198633/en/
Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing of its Series A financing, the expansion of the scientific team, and the advancement of its therapeutic programs. In his new role, he will lead ATB’s strategy and senior leadership team as the Company prepares to enter clinical development.
As part of this transition, co-founder Bertrand Magy will move into the role of Chief Operating Officer, and co-founder Max Houry will assume the role of Chief Business Officer. Mr. Magy will focus on operations and the continued development of ATB’s proprietary antibody weaponization technology platform, while Mr. Houry will lead business development, strategic partnerships, and licensing activities.
This leadership transition supports ATB’s next stage of growth, with a focus on the validation of ATB’s platform and preparing for clinical development.
Mark Throsby, PhD, Chief Executive Officer of ATB Therapeutics, said: “Since the closing of our EUR 54 million Series A financing in 2024, we have made strong progress in strengthening our team, expanding our capabilities, and validating our science. I am honored to take on the role of CEO and excited to continue working closely with Bertrand, Max, the Board, and the broader ATB team as we advance our mission and bring atbodies closer to patients.”
Bertrand Magy, PhD, co-founder of ATB Therapeutics, said: “From the beginning, ATB has been driven by a shared vision to create a new class of therapies with real patient impact. It has been an extraordinary scientific and entrepreneurial journey, and I am very proud of what we have accomplished so far. I look forward to continuing to work closely with Mark, Max, and the team as we enter this next chapter.”
Max Houry, co-founder of ATB Therapeutics, said: “Over the past years, we have transformed an initial scientific concept into a promising therapeutic platform. Together with Bertrand and Mark, we have built strong foundations for the Company’s future. In my new role, I will focus on translating that momentum into strategic partnerships and business opportunities that can help bring meaningful therapies to patients.”
Mark Throsby earned his PhD in Immunology from Monash University in Melbourne, Australia, and spent four years as a research fellow at CNRS in Paris. He began his industry career at Crucell (acquired by Johnson & Johnson for USD 2.4 billion), where he spent eight years in various roles, including Director of Antibody Discovery. Prior to joining ATB, he served at Merus (acquired by Genmab for USD 8.0 billion) as COO and later CSO, where he played a key role in the development of the bispecific antibody therapeutics petosemtamab and zenocutuzumab. He is an expert in antibody engineering and immunology, with more than a dozen granted patents and > 50 peer-reviewed publications.
About ATB Therapeutics
ATB Therapeutics is an emerging biotechnology company developing atbodies, the next‑generation of weaponized antibody therapies powered by a proprietary portfolio of differentiated payloads with unique modes of action. By integrating these innovative payloads into advanced antibody formats, ATB Therapeutics aims to deliver more precise and potent treatment options for patients across oncology and autoimmune diseases. The company is building a new class of targeted therapeutics designed to overcome limitations of conventional approaches and address significant unmet medical needs.
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth
ANAHEIM, Calif. (AP) — Athletics starter J.T. Ginn took a no-hitter and a one-run lead into the ninth inning Monday night.
Six pitches later, he walked off the mound with a heartbreaking loss.
Adam Frazier lined a leadoff single in the bottom of the ninth and Zach Neto followed with a two-run homer that gave the Los Angeles Angels a 2-1 victory, stunning Ginn and the A’s while snapping a six-game skid.
“Obviously a tough game," Ginn said. "Just keep your head up and keep moving forward. It’s just the nature of the game that we play. I attack the zone and I live with that.”
Frazier lined an 0-2 pitch over shortstop for a clean single, giving Los Angeles only its third baserunner. Neto then drove a 2-0 sinker to center field for his eighth home run of the season.
“Just a crazy game to play," Ginn said. "I fell behind 2-0, threw a good sinker, and he was waiting on it and put a good swing on it. So, tip your cap to him.”
Ginn (2-2) was trying for the first no-hitter in the majors since Shota Imanaga combined with two Chicago Cubs relievers for a 12-0 win over Pittsburgh on Sept. 4, 2024. The previous pitcher to throw a complete-game no-hitter was Blake Snell for the San Francisco Giants against Cincinnati on Aug. 2, 2024.
The most recent A's no-hitter was thrown by Mike Fiers in May 2019 against Cincinnati.
Ginn threw a career-high 105 pitches, 64 for strikes. He struck out 10, walked one and hit Neto with a pitch in the sixth.
The right-hander from Mississippi, who turns 27 on Wednesday, fanned all three batters in the seventh to give him 10 strikeouts — setting a career high. But he became the sixth major league pitcher since at least 1974 to allow no hits or runs in the first eight innings of a game and still take the loss. Rich Hill was the previous one, for the Los Angeles Dodgers against Pittsburgh in August 2017.
“J.T. dominated all night. For him to walk off the mound with a loss there, it hurts, obviously,” Athletics manager Mark Kotsay said. "He pitched probably the best game he’s pitched in his big league career, and to have an opportunity to get a no-hitter, and two hits later you walk off with a loss, it’s tough. I had full confidence in him going out there in that inning at 100 pitches and trying to get it done. It just didn’t work out.”
Kotsay had lefty Hogan Harris warming up in the bullpen during the ninth inning and planned to bring him in to face Mike Trout, who was on deck when the game ended. Kotsay hoped Ginn, whose sinker had been effective all night, could induce a groundball from Neto.
“Hindsight’s always 20-20,” Kotsay said. “It easily could have went the other direction.”
Pinch-hitter Lawrence Butler put the A's ahead 1-0 with an RBI single in the top of the ninth. The A's then loaded the bases before Angels reliever Chase Silseth got slugger Nick Kurtz to ground into an inning-ending double play.
“Kurtz doesn’t hit the ball on the ground a ton and they get out of that inning and momentum shifted a little bit,” Kotsay said. "It would have been nice to add on in that inning and give (Ginn) a little more cushion.”
It was the 30th career start for Ginn, who made his major league debut in August 2024.
“He did such a phenomenal job all night keeping guys off balance. His stuff was nasty. Just kind of rolling, you know, and then it’s gut-wrenching stuff in the ninth for it to end that way. It definitely sucks right now," Athletics catcher Shea Langeliers said. "Baseball will humble you in all sorts of ways. ... It’s going to be hard to flush this one.”
The Angels haven't been no-hit since Sept. 11, 1999 — the longest active streak in the majors. In that game, they lost 7-0 at Minnesota, shut down by Twins pitcher Eric Milton.
The last visiting pitcher to throw a no-hitter against the Angels in Anaheim was Rangers right-hander and Hall of Famer Burt Blyleven on Sept. 22, 1977, in a 6-0 Texas triumph.
The last A’s starting pitcher to lose a no-hitter in the ninth inning was Vida Blue against Detroit in 1976.
AP MLB: https://apnews.com/hub/mlb
Los Angeles Angels' Zach Neto (9) is greeted by teammates after hitting a walk0ff home run during the ninth inning of a baseball game against the Athletics, Monday, May 18, 2026, in Anaheim, Calif. (AP Photo/William Liang)
Los Angeles Angels' Zach Neto (9) reacts after hitting a walkoff home run during the ninth inning of a baseball game against the Athletics, Monday, May 18, 2026, in Anaheim, Calif. (AP Photo/William Liang)
Los Angeles Angels' Zach Neto is douced after hitting a walkoff home run during the ninth inning of a baseball game against the Athletics, Monday, May 18, 2026, in Anaheim, Calif. (AP Photo/William Liang)
Athletics' Tyler Soderstrom reacts during the sixth inning of a baseball game against the Los Angeles Angels, Monday, May 18, 2026, in Anaheim, Calif. (AP Photo/William Liang)
Athletics pitcher J.T. Ginn delivers during the first inning of a baseball game against the Los Angeles Angels, Monday, May 18, 2026, in Anaheim, Calif. (AP Photo/William Liang)
